Saturday 17 October 2026 Export XENE’s income statement to Excel — free account

Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $7.5 million, down 20.5% from fiscal 2022. In the quarter to June 2026, revenue grew 100.7%, EPS fell 3.74% and free cash flow fell 48.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

33.55 0.78 −2.27%

Follow XENE

Alert me

Market cap: $3.3B
P/E: 0.0×
Fwd P/E: −10.7×
Dividend yield: —
F-score: n/a
Altman Z: 37.76
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 1.68

Total sells 21.97

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	2	—
Sell	1	1	1	—	6	—	—	2	—	2	—	—

Insider Ownership 7.89%

Capital & Financial Ratios $m

Market Cap 3,320.00

Revenue 16.93

Net Income (409.19)

Free Cash Flow (338.53)

Net Debt (930.69)

Current Ratio 21.02

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (10.70)

P/S ratio 197.35

P/B ratio 2.69

Past 5Y EPS Growth —

This Y EPS Growth (5.62%)

Next Y EPS Growth (1.77%)

Next Y revenue growth (83.24%)

Next 5Y EPS Growth 8.32%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 63.99%

10-year low 10-year high

P/B against its own 10 years 38.78%

10-year low 10-year high

EV/Sales against its own 10 years 58.78%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	638	627	549	931
Receivables	1	1	1	2
Inventory	—	—	—	—
Other	—	—	—	—
	645	635	561	946

	2023	2024	2025	Q'26
Payables	26	34	40	44
ST’ Debt	—	—	—	—
Other	—	—	—	—
	27	36	42	45

Compound Annual Growth %

	10y	5y	3y
Sales	3.15%	89.00%	(38.45%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	25.29%	27.69%	(6.92%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	8	—	—	—	8
’22	9	1	0	—	9
’21	4	2	8	4	18
’20	7	13	7	5	32
’19	—	—	4	3	7
’17	0	0	0	0	0

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(89)	(95)	—	—	—
’25	(62)	(64)	(72)	(81)	(279)
’24	(46)	(31)	(50)	(54)	(181)
’23	(34)	(33)	(48)	(35)	(151)
’22	(18)	(17)	(30)	(33)	(98)
’21	(21)	(13)	(15)	(21)	(70)
’20	(13)	(11)	(11)	(13)	(48)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(89)	(96)	—	—	—
’25	(62)	(64)	(72)	(82)	(280)
’24	(46)	(33)	(50)	(55)	(184)
’23	(37)	(35)	(49)	(35)	(157)
’22	(19)	(17)	(31)	(34)	(101)
’21	(21)	(14)	(15)	(21)	(72)
’20	(14)	(11)	(12)	(14)	(51)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(1.17)	(1.11)	—	—	—
’25	(0.83)	(1.07)	(1.15)	(1.31)	(4.36)
’24	(0.62)	(0.75)	(0.81)	(0.84)	(3.01)
’23	(0.63)	(0.72)	(0.73)	(0.64)	(2.73)
’22	(0.35)	(0.55)	(0.57)	(0.57)	(2.06)
’21	(0.42)	(0.51)	(0.36)	(0.57)	(1.77)
’20	(0.22)	0.00	(0.25)	(0.34)	(0.81)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	5.65	2.10	2.70	6.17	7.00	13.23	24.60	27.99	35.53	26.74	Analyst estimates 2026–2028 Powerpack
	High	8.75	9.95	15.92	14.95	18.45	36.42	41.39	47.00	50.99	46.60
People
People	Employees	94	81	92	104	129	153	213	259	327	370
	Revenue/emp, $m	0.02	0.00	0.00	0.07	0.25	0.12	0.04	0.00	0.00	0.02
Income, $m
Income, $m	Revenue	2	0	—	7	32	18	9	—	—	8
	Gross margin, %	100.00	100.00	0.00	100.00	100.00	100.00	100.00	—	—	100.00
	EBT	(23)	(31)	(35)	(42)	(29)	(79)	(125)	(183)	(238)	(345)
	EBT margin, %	(1,275.49)	(9,872.67)	0.00	(609.43)	(90.45)	(427.88)	(1,327.70)	0.00	0.00	(4,598.59)
	Net income	(23)	(31)	(34)	(42)	(29)	(79)	(125)	(182)	(234)	(346)
	Depreciation	1	1	1	1	1	1	2	2	3	3
Per share, $
Per share, $	Revenue	0.12	0.02	0.00	0.26	0.93	0.42	0.16	0.00	0.00	0.09
	Earnings	(1.48)	(1.71)	(1.63)	(1.54)	(0.81)	(1.77)	(2.06)	(2.73)	(3.01)	(4.36)
	Cash flow	(1.26)	(1.60)	(1.79)	(0.18)	(1.39)	(1.59)	(1.63)	(2.26)	(2.33)	(3.52)
	Capex	(0.02)	(0.02)	(0.03)	(0.05)	(0.08)	(0.05)	(0.05)	(0.08)	(0.04)	(0.01)
	Free cash flow	(1.28)	(1.61)	(1.81)	(0.23)	(1.47)	(1.64)	(1.67)	(2.34)	(2.37)	(3.53)
	Book value	4.12	2.00	5.32	3.55	4.96	12.61	11.92	13.87	9.69	7.34
	Shares, m	15	18	19	26	35	44	61	67	78	79
Valuation, ×
Valuation, ×	P/E	0.00	0.00	—	0.00	0.00	0.00	0.00	—	—	0.00
	P/S	67.45	166.55	—	47.84	16.52	73.92	171.27	—	—	209.76
	P/B	1.90	1.44	—	4.04	3.25	2.51	3.13	—	—	6.11
	EV/Sales	31.88	48.02	—	30.14	11.84	45.44	128.33	—	—	178.92
	EV/FCF	(2.90)	(0.51)	—	(35.98)	(7.50)	(11.71)	(16.68)	—	—	(10.82)
Cash, $m
Cash, $m	Operating cash flow	(20)	(29)	(35)	(5)	(48)	(70)	(98)	(151)	(181)	(279)
	Capex	0	0	(1)	(1)	(3)	(2)	(3)	(6)	(3)	(1)
	Free cash flow	(20)	(29)	(35)	(6)	(51)	(72)	(101)	(157)	(184)	(280)
Balance, $m
Balance, $m	Working capital	62	41	117	101	167	545	578	618	600	519
	Total debt	—	7	15	16	3	8	10	—	—	—
	Net debt	(64)	(37)	(104)	(126)	(177)	(552)	(592)	(638)	(627)	(549)
	Shareholders’ equity	64	36	103	92	171	550	721	928	755	582
Returns, %
Returns, %	ROA	(34.99)	(54.05)	(37.52)	(29.64)	(16.63)	(20.25)	(18.84)	(21.22)	(26.58)	(48.34)
	ROIC	0.00	0.00	0.00	0.00	0.00	0.00	(62.37)	(46.16)	(136.38)	(709.28)
	ROE	(36.81)	(61.51)	(48.09)	(44.52)	(22.60)	(21.84)	(19.77)	(22.12)	(27.85)	(51.76)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Mar 2025

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
ARQT Arcutis Biotherapeutics, Inc.	$3.7B	131×	196×	+59.33% (above 0%: growing)	n/m	+227.96% (above 0%: growing)	91.58%	12.65%	Compare
TLX Telix Pharmaceuticals Limited	$3.6B	—	—	—	—	−44.78% (below 0%: shrinking)	—	—	Compare
TARS Tarsus Pharmaceuticals, Inc.	$3.5B	— (loss-making)	— (loss-making)	+69.41% (above 0%: growing)	n/m	+288.08% (above 0%: growing)	93.03%	(11.45%)	Compare
VKTX Viking Therapeutics, Inc.	$3.5B	— (loss-making)	—	—	n/m	−165.98% (below 0%: shrinking)	0.00%	0.00%	Compare
ACAD ACADIA Pharmaceuticals Inc.	$3.4B	8.5×	55.6×	+16.40% (above 0%: growing)	+12.50% (above 0%: growing)	+50.32% (above 0%: growing)	90.81%	12.29%	Compare
XENE Xenon Pharmaceuticals Inc.	$3.3B	— (loss-making)	— (loss-making)	+100.70% (above 0%: growing)	n/m	−48.57% (below 0%: shrinking)	100.00%	0.00%
IDYA IDEAYA Biosciences, Inc.	$3.3B	— (loss-making)	— (loss-making)	+125.77% (above 0%: growing)	n/m	−41.09% (below 0%: shrinking)	100.00%	(1,380.73%)	Compare
CELC Celcuity, Inc.	$3.0B	— (loss-making)	—	—	n/m	−53.27% (below 0%: shrinking)	0.00%	0.00%	Compare
DNLI Denali Therapeutics Inc.	$2.9B	— (loss-making)	— (loss-making)	−89.74% (below 0%: shrinking)	n/m	−22.91% (below 0%: shrinking)	97.42%	(3,622.11%)	Compare
Median of peers	$3.4B	—	—	+59.33%	—	−32.00%	91.58%	0.00%

All 614 Biotechnology stocks →

Xenon Pharmaceuticals Inc. (XENE) key facts

Concern: Xenon Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $7.5 million, down 20.5% from fiscal 2022.
Xenon Pharmaceuticals Inc. (XENE) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, XENE traded at $33.55, a market capitalization of $3.3 billion.
Return on equity was −51.8% and debt-to-equity 0.00.
Its Altman Z-score is 37.76 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.